The LiBBY trial tested a supervised THC-plus-CBD oil for agitation in late-stage dementia, not for early memory concerns. LiBBY stands for Life's End Benefits of cannabidiol and tetrahydrocannabinol, and it enrolled 120 hospice-eligible U.S. adults with dementia and clinically significant agitation.
For adult children, the distinction matters. Agitation here means persistent restlessness, aggression, or distress that disrupts care at the end of life. The trial found less agitation with active treatment, but only in that supervised end-of-life setting.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who was studied in LiBBY?
- What did treatment change?
- Who was not studied?
- What should adult children do now?
Who was studied in LiBBY?
Participants averaged about age 80, and 55% were female. Three-quarters lived in community settings, with care delivered through 10 home-visit sites.
All had Alzheimer's or another dementia and qualified for hospice care or were already receiving it. All had clinically significant agitation at entry, according to the Alzheimer's Association report on the 12-week Phase 2 trial first presented July 14, 2026 at AAIC in London AAIC meeting release.
What did treatment change?
Active treatment was 2 mg THC plus 100 mg CBD in a novel oral oil, taken twice daily. It was a purified study formulation, compared with matching placebo. Agitation scores fell more on active treatment by week 2, about 6.27 points more than placebo on the Cohen-Mansfield Agitation Inventory.
That scale rates common agitated behaviors in dementia, and separation persisted through week 12, according to NeurologyLive NeurologyLive trial summary. Global improvement reached 83.9% at week 2 and 87.2% at week 12 on active drug, versus 30.5% and 23.6% on placebo. In plain terms, nearly 9 in 10 treated patients were rated improved at study end.
Who was not studied?
The trial did not include people with early or mild dementia without agitation. It also did not include adults under age 40 or people who did not meet advanced-dementia and hospice thresholds.
Other exclusions were recent cannabinoid use in the prior three weeks and cannabinoid allergy. For families, a useful check is:.
- parent has early memory concerns but no agitation — not studied
- parent is younger, not advanced, or not hospice-eligible — not studied
- symptoms involve sleep, anxiety, or appetite alone — not the tested use
- interest is in a store, dispensary, or over-the-counter product — not the tested product
What should adult children do now?
Do not use LiBBY as a reason to give a parent cannabis from a store or dispensary. The tested oil was made for the study and given under supervision for end-of-life agitation. The safety pattern also needs weight in decisions.
Serious adverse events, serious infections, and deaths were higher on active treatment than placebo, even though overall adverse events looked similar, according to NeurologyLive NeurologyLive safety results. If your parent receives hospice or palliative care and has distressing agitation, ask the hospice team about current agitation options and trial availability. Bring the medication list, allergy history, infection risk, and goals of comfort care to that visit.
You Might Also Like
- p-tau217 Findings a Decade Before Alzheimer’s Symptoms in 2026: Who Was Studied and Who Was Not for Adult Children
- AAIC 2026 p-tau217 Alzheimer’s Risk Prediction Research: Who Was Studied and Who Was Not for Adult Children
- LatAm-FINGERS Lifestyle Coaching Findings Across 11 Countries in 2026: How Family Caregivers Can Build a Realistic Brain Health Plan
